Skip to content

Vaxcyte, Inc. PCVX Operating Lease Liability - Undiscounted Excess Amount

Operating Lease Liability - Undiscounted Excess Amount at other companies

Moderna logo
ModernaMRNA
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s operating lease liability - undiscounted excess amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s operating lease liability - undiscounted excess amount?
Vaxcyte, Inc. (PCVX) reported operating lease liability - undiscounted excess amount of $44.82M in Q1 2026.
How has Vaxcyte, Inc.'s operating lease liability - undiscounted excess amount changed year-over-year?
Vaxcyte, Inc.'s operating lease liability - undiscounted excess amount increased by 22.2% year-over-year, from $36.69M to $44.82M.
What does operating lease liability - undiscounted excess amount mean?
This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.